GSK plc

GSKPhase 3

GSK plc is one of the world's leading pharmaceutical companies, headquartered in London, with operations in over 100 countries. The company has transformed from a traditional pharmaceutical giant into a focused biopharma company through strategic divestitures and increased R&D investment. GSK maintains leadership positions in respiratory diseases, HIV treatment, vaccines, and has a growing oncology portfolio. The company is publicly traded on the London Stock Exchange and NYSE with a market capitalization exceeding $100 billion.

Market Cap

$103.7B

Employees

95,000-100,000

Focus

Biotech

GSK · Stock Price

USD 51.84+8.56 (+19.78%)

Historical price data

AI Company Overview

Technology Platform

GSK leverages human genetics, AI/ML analytics, and platform technologies including cell and gene therapy, mRNA vaccines, and advanced manufacturing to discover and develop innovative medicines and vaccines.

Pipeline Snapshot

130

130 drugs in pipeline, 28 in Phase 3

Drug	Indication	Stage
clobetasol propionate 0.05% + Vehicle / Placebo	Dermatitis, Chronic	Approved
Acitretin (also called U0279) + Placebo + Etanercept	Plaque Psoriasis	Approved
Belimumab plus Early Vaccination + Belimumab plus Late Vaccination	Systemic Lupus Erythematosus	Approved
Clindamycin and BPO 5% gel + Clindamycin phosphate and benzoyl peroxide 2.5% gel...	Acne Vulgaris	Approved
Placebo plus standard therapy + Belimumab 10 mg/kg plus standard therapy + Stand...	Systemic Lupus Erythematosus	Approved

Opportunities

GSK has significant growth opportunities through its focused biopharma strategy, including expanding its respiratory franchise globally, penetrating the HIV prevention market with long-acting therapies, and advancing its oncology pipeline.

The company's strong vaccine capabilities and mRNA platform position it well for future pandemic preparedness and endemic disease markets.

Risk Factors

Key risks include patent cliffs on major products like Advair and Trelegy, intense competition in core therapeutic areas, regulatory challenges for new product approvals, and the inherent risks of clinical development failures.

The company also faces pricing pressure in key markets and potential supply chain disruptions.

Competitive Landscape

GSK competes directly with pharmaceutical giants like Pfizer, J&J, Merck, and AstraZeneca across multiple therapeutic areas. The company differentiates through its leadership in respiratory diseases, strong vaccine portfolio, focused HIV franchise, and emerging oncology capabilities, though it faces intense competition from both large pharma and specialized biotech companies.

Publications

Pipeline

130